Inventiva says Phase 3 NATiV3 lanifibranor MASH trial topline data due in Q4 2026

• Inventiva flagged new Phase 1 and Phase 2 analyses on lanifibranor for MASH, slated for presentation at the Paris MASH Meeting on Sept. 10-11, 2026.
• The studies showed improved metabolic measures tied to cardiovascular risk in patients with MASH, including those with or without type 2 diabetes.
• Separate preclinical work supported a differentiated fluid and cardiac safety profile versus some other PPAR-class drugs.
• Lanifibranor remains in the Phase 3 NATiV3 trial, with topline results expected in Q4 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inventiva SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609081600OMX_____CNEWS_EN_GNW1001261713_en) on September 08, 2026, and is solely responsible for the information contained therein.